Scientific Rationale for the Possible Inhaled Corticosteroid Intraclass Difference in the Risk of Pneumonia in COPD

Overview

Journal Int J Chron Obstruct Pulmon Dis

Publisher Dove Medical Press

Specialty Pulmonary Medicine

Date 2017 Nov 2

PMID 29089754

Citations 27

Authors

Christer Janson

Georgios Stratelis

Anna Miller-Larsson

Tim W Harrison

Kjell Larsson

Affiliations

Soon will be listed here.

Abstract

Inhaled corticosteroids (ICSs) treatment combined with long-acting β-adrenoceptor agonists (LABAs) reduces the risk of exacerbations in COPD, but the use of ICSs is associated with increased incidence of pneumonia. There are indications that this association is stronger for fluticasone propionate than for budesonide. We have examined systematic reviews assessing the risk of pneumonia associated with fluticasone propionate and budesonide COPD therapy. Compared with placebo or LABAs, we found that fluticasone propionate was associated with 43%-78% increased risk of pneumonia, while only slightly increased risk or no risk was found for budesonide. We have evaluated conceivable mechanisms which may explain this difference and suggest that the higher pneumonia risk with fluticasone propionate treatment is caused by greater and more protracted immunosuppressive effects locally in the airways/lungs. These effects are due to the much slower dissolution of fluticasone propionate particles in airway luminal fluid, resulting in a slower uptake into the airway tissue and a much longer presence of fluticasone propionate in airway epithelial lining fluid.

Citing Articles

Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD.

Lee E, Kim Y, Hwang Y, Yoo K, Lee S, Jung K Sci Rep. 2023; 13(1):8183.

PMID: 37210420 PMC: 10199945. DOI: 10.1038/s41598-023-35223-3.

Exploring the appropriateness of prescribing practice of inhaled pharmacotherapy among Aboriginal Australians in the Top End Northern Territory of Australia: a retrospective cohort study.

Heraganahally S, Howarth T, Issac S, Lloyd A, J Ravichandran S, Abeyaratne A BMJ Open Respir Res. 2023; 10(1).

PMID: 36878611 PMC: 9990608. DOI: 10.1136/bmjresp-2022-001508.

Risk of Tuberculosis Caused by Fluticasone Propionate versus Budesonide in Chronic Obstructive Pulmonary Disease: A Nationwide Population-Based Study.

Yu I, Park S, Hong S, Chang M, Lee S, Yong S J Pers Med. 2022; 12(7).

PMID: 35887686 PMC: 9321025. DOI: 10.3390/jpm12071189.

Inhaled Corticosteroids Selectively Alter the Microbiome and Host Transcriptome in the Small Airways of Patients with Chronic Obstructive Pulmonary Disease.

Yip W, Li X, Koelwyn G, Milne S, Leitao Filho F, Xi Yang C Biomedicines. 2022; 10(5).

PMID: 35625847 PMC: 9138653. DOI: 10.3390/biomedicines10051110.

Statistical Analysis and Machine Learning Prediction of Disease Outcomes for COVID-19 and Pneumonia Patients.

Zhao Y, Zhang R, Zhong Y, Wang J, Weng Z, Luo H Front Cell Infect Microbiol. 2022; 12:838749.

PMID: 35521216 PMC: 9063041. DOI: 10.3389/fcimb.2022.838749.

References

Brattsand R, Miller-Larsson A . The role of intracellular esterification in budesonide once-daily dosing and airway selectivity. Clin Ther. 2003; 25 Suppl C:C28-41. DOI: 10.1016/s0149-2918(03)80304-1. View

Bur M, Rothen-Rutishauser B, Huwer H, Lehr C . A novel cell compatible impingement system to study in vitro drug absorption from dry powder aerosol formulations. Eur J Pharm Biopharm. 2008; 72(2):350-7. DOI: 10.1016/j.ejpb.2008.07.019. View

Miller-Larsson A, Mattsson H, Hjertberg E, Dahlback M, Tunek A, BRATTSAND R . Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos. 1998; 26(7):623-30. View

Anzueto A, Ferguson G, Feldman G, Chinsky K, Seibert A, Emmett A . Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD. 2009; 6(5):320-9. DOI: 10.1080/15412550903140881. View

Jenkins C, Jones P, Calverley P, Celli B, Anderson J, Ferguson G . Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009; 10:59. PMC: 2714501. DOI: 10.1186/1465-9921-10-59. View

Pauwels R, Lofdahl C, Laitinen L, Schouten J, Postma D, Pride N . Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999; 340(25):1948-53. DOI: 10.1056/NEJM199906243402503. View

Sharafkhaneh A, Southard J, Goldman M, Uryniak T, Martin U . Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med. 2011; 106(2):257-68. DOI: 10.1016/j.rmed.2011.07.020. View

Berenson C, Garlipp M, Grove L, Maloney J, Sethi S . Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease. J Infect Dis. 2006; 194(10):1375-84. DOI: 10.1086/508428. View

Blum C, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I . Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015; 385(9977):1511-8. DOI: 10.1016/S0140-6736(14)62447-8. View

10.

Garcha D, Thurston S, Patel A, Mackay A, Goldring J, Donaldson G . Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax. 2012; 67(12):1075-80. DOI: 10.1136/thoraxjnl-2012-201924. View

11.

Provost K, Smith M, Miller-Larsson A, Gudleski G, Sethi S . Bacterial regulation of macrophage bacterial recognition receptors in COPD are differentially modified by budesonide and fluticasone propionate. PLoS One. 2019; 14(1):e0207675. PMC: 6345465. DOI: 10.1371/journal.pone.0207675. View

12.

van den Brink K, Boorsma M, Staal-van den Brekel A, Edsbacker S, Wouters E, Thorsson L . Evidence of the in vivo esterification of budesonide in human airways. Br J Clin Pharmacol. 2008; 66(1):27-35. PMC: 2485262. DOI: 10.1111/j.1365-2125.2008.03164.x. View

13.

Haghi M, Traini D, Postma D, Bebawy M, Young P . Fluticasone uptake across Calu-3 cells is mediated by salmeterol when deposited as a combination powder inhaler. Respirology. 2013; 18(8):1197-201. DOI: 10.1111/resp.12146. View

14.

Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J . Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015; 313(7):677-86. DOI: 10.1001/jama.2015.88. View

15.

Donnelly L, Barnes P . Defective phagocytosis in airways disease. Chest. 2012; 141(4):1055-1062. DOI: 10.1378/chest.11-2348. View

16.

Ferguson G, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C . Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med. 2008; 102(8):1099-108. DOI: 10.1016/j.rmed.2008.04.019. View

17.

Wedzicha J, Calverley P, Seemungal T, Hagan G, Ansari Z, Stockley R . The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2007; 177(1):19-26. DOI: 10.1164/rccm.200707-973OC. View

18.

Edsbacker S, Brattsand R . Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available data. Ann Allergy Asthma Immunol. 2002; 88(6):609-16. DOI: 10.1016/S1081-1206(10)61893-5. View

19.

Morjaria J, Rigby A, Morice A . Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study. Lung. 2017; 195(3):281-288. PMC: 5437199. DOI: 10.1007/s00408-017-9990-8. View

20.

Larsson K, Janson C, Lisspers K, Jorgensen L, Stratelis G, Telg G . Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. J Intern Med. 2013; 273(6):584-94. DOI: 10.1111/joim.12067. View